Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background:Several studies suggest links between cancer and tricyclic antidepressant use.Methods:A case-control study using the General Practice Research Database examined whether previous tricyclic usage was associated with reduced incidence of brain (with glioma as a sub-category), breast, colorectal, lung and prostate cancers. Conditional logistic regression adjusted for age, gender, general practice, depression, smoking, body mass index, alcohol use and non-steroidal anti-inflammatory drug use.Results:A total of 31 953 cancers were identified, each matched with up to two controls. We found a statistically significant reduction in tricyclic prescriptions compared with controls in glioma (odds ratio (OR) 0.59, 95% confidence interval (CI)0.42-0.81) and colorectal cancer patients (OR0.84, CI0.75-0.94). These effects were dose-dependent (P-values for trend, glioma0.0005, colorectal0.001) and time-dependant (P-values for trend glioma0.0005, colorectal0.0086). The effects were cancer-type specific, with lung, breast and prostate cancers largely unaffected by antidepressant use.Conclusion:The biologically plausible, specific and dose- and time-dependant inverse association that we have found suggests that tricyclics may have potential for prevention of both colorectal cancer and glioma. © 2011 Cancer Research UK All rights reserved.

Original publication

DOI

10.1038/sj.bjc.6605996

Type

Journal article

Journal

British Journal of Cancer

Publication Date

04/01/2011

Volume

104

Pages

193 - 197